Investment Highlights for Delpor, Inc.

Delpor, Inc.
150 North Hill Drive, Suite 25
Brisbane, CA 94005
Phone: (415) 480-6870
https://delpor.com

• Delpor is focused on advancing clinical-stage development of once-yearly therapeutics for chronic conditions.
  
  
• The Company has pioneered a platform technology capable of sustaining drug release for up to one year, promising transformative advancements in long-term therapeutic delivery.
  
  
• With two clinical assets already in development and a robust pipeline, the Company demonstrates promising growth potential in delivering innovative treatments to address unmet medical needs. 
  
  
• Delpor’s pipeline includes:

• • DLP-114 (Once-Yearly Risperidone), its lead asset, targeting schizophrenia maintenance with a 6 or 12-month dosing interval, in Phase 2b (Phase 3 expected during 2025); 
    
    
  • DLP-160 (Once-Yearly Naltrexone) for Opioid Use Disorder (OUD), in Phase 1 (Phase 1b expected in 2025), also offering a 6 or 12-month dosing option; 
    
    
  • DLP-208 (6-Month Tizanidine), in preclinical development for spasticity, focused on a 6-month dosing interval, with Phase 1 expected in 2025; and
    
    
  • Undisclosed molecules targeting CNS, diabetes, obesity, and other conditions, which have shown promising potential for future development, in preclinical development or feasibility evaluation. 

• The long-acting antipsychotics market, valued at over $6 billion, is growing at approximately 10%, while the U.S. OUD market, exceeding $2 billion, is expanding at a rate of around 10%. 
  
  
• Delpor’s technology stands out as the sole option within the target markets capable of providing once-yearly dosing, reversibility, a one-day washout period, smooth PK, and no initiation dosing requirement.
  
  
• In recent years, progress in drug development for schizophrenia has slowed, while the pharmaceutical industry has largely overlooked substance use disorder. Delpor is working to revolutionize treatments for CNS conditions with its focus on product longevity and stability.
  
  
• Primary market research has validated the Company’s adoption, pricing, and reimbursement strategies, with physician and payer feedback indicating potential for premium pricing, favorable reimbursement, and potential peak sales of $2 billion for the Company’s lead asset, according to the Company’s recently commissioned market research study by Symphony Health and KMK Consulting.
  
  
• The Company’s regulatory strategy prioritizes the utilization of the 505(b)(2) pathway, which presents reduced technical risk while offering substantial commercial opportunities. The primary focus lies in pursuing 505(b)(2) submissions, aiming to minimize or eliminate the necessity for efficacy trials in most instances.
  
  
• Delpor holds 25 issued patents across 9 patent families, with an additional 30+ patent applications currently pending.
  
  
• Delpor’s team comprises experienced management personnel with a track record of developing products in drug delivery and drug/device combination fields, as well as achieving successful exit strategies.
  
  
• The Company has raised a total of approximately $40 million, with investments from Kairos Ventures, Ulu Ventures, HIT, Seedfolio, Cloudstone, HTH (part of the Zambon Group), Mario Family Partners, and other contributors. Delpor has been awarded approximately $20 million in non-dilutive funding from the NIH, with the potential for an additional $15 million over the next 12 months. Additionally, the target for the Series C round is approximately $40 to $60 million.